Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.65 |
| ▸ | CDK9 | P50750 | 11/20 | 0.65 |
| ▸ | CDK7 | P50613 | 12/20 | 0.58 |
| ▸ | CDK1 | P06493 | 11/20 | 0.58 |
| ▸ | CDK4 | P11802 | 11/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 10/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.58 |
| ▸ | CCNH | P51946 | 10/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.58 |
| ▸ | CCND1 | P24385 | 9/20 | 0.58 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.58 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.58 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295957 | 0.83 | CDK2 (0.64) | CDK2CDK9CDK7CDK1CDK4 | |
| SCHEMBL3301221 | 0.83 | CDK2 (0.66) | CDK2CDK9CDK7CDK1CDK4 | |
| SCHEMBL3303025 | 0.79 | CDK2 (1.00) | CDK2CDK9CDK7CDK1CDK4 | |
| SCHEMBL3296793 | 0.78 | CDK2 (0.67) | CDK2CDK9CDK7CDK1CDK4 | |
| SCHEMBL3298930 | 0.77 | CDK2 (0.66) | CDK2CDK9CDK7CDK1CDK4 | |
| SCHEMBL29829223 | 0.73 | CDK2 (1.00) | CDK2CDK9CDK7CDK1CDK4 | |
| SCHEMBL3336119 | 0.73 | CDK2 (1.00) | CDK2CDK9CDK7CDK1CDK4 | |
| SCHEMBL1378920 | 0.73 | CDK2 (1.00) | CDK2CDK9CDK7CDK1CDK4 | |
| SCHEMBL1374884 | 0.73 | CDK2 (1.00) | CDK2CDK9CDK7CDK1CDK4 | |
| SCHEMBL1380075 | 0.73 | CDK2 (1.00) | CDK2CDK9CDK7CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592581-B2 | Trisubstituted purine derivatives | CYCLACEL LIMITED (GB) | 2013-11-26 | — | — | US | claimed |
| US-20100093769-A1 | COMPOUNDS | CYCLACEL LIMITED (GB) | 2010-04-15 | — | — | US | claimed |
| US-8592581-B2 | Trisubstituted purine derivatives | CYCLACEL LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2139893-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES | CYCLACEL LTD (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20100093769-A1 | COMPOUNDS | CYCLACEL LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2139893-A2 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES | Cyclacel Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122767-A2 | 2, 6, 9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTI PROLIFERATIVE PROPERTIES | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093769-A1 | COMPOUNDS | CCR9, NPY1R, BCL9 | CDK2 1751/4885CDK9 57/4885CDK7 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.